Genmab — Oktober 2019

[Sukkeralf]

Its the target combination and not the delivery that counts

[Sukkeralf]

Hope to see data from this one at ASH

[E_L]

no, i thought 1 being Dara Anti-BCMAxCD3 and the second Dara Anti-GPRC5DxCD3

[E_L]

(about IV and SC; i saw yesterday that AbbVie is now using "Administered by subcutaneous injection (preferred) OR intravenously (IV)" in the Venetoclax trial it just reopened again (and wehre they added a few arms)) https://clinicaltrials.gov/ct2/history/NCT03314181?A=15&B=16&C=merged#StudyPageTop

[Sukkeralf]

Yes thats 2 duobodies

[E_L]

ok. if i count correct we now have 8 then. 2 to go. Will be interesting to see what happens when all 10 are used, will they
enlarge the program at some point.

[Sukkeralf]

Remember Janssen has the right to 20 DuoBody programs

[Sukkeralf]

https://ir.genmab.com/news-releases/news-release-details/genmab-announces-expansion-duobody-platform-collaboration/

[peter12]

Det er lidt af en milestone

[peter12]

Men det er efter 20 programmer ....

[Sukkeralf]

Fra årsregnskabet: As of December 31, 2018, Janssen had exercised 14
licenses under this collaboration. No further options remain
for use by Janssen.

[E_L]

ok, thanks for updating me here

[E_L]

so the difference between the 14 and 20? maybe to do with an expiration time?

[Sukkeralf]

Im not sure how to understand that last sentence "No further options remain for use by Janssen".

[Sukkeralf]

It could fit with a 5 year timeline to start the programs - but lets ask Jan at the coming Q&A

[Sukkeralf]

Maybe a coincidence but Janssen signed at deal for 6 programs with Zymeworks end 2017 or beginning of 2018

[Sukkeralf]

Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

(www.fiercebiotech.com)

[E_L]

ah. ok. no that is not coincidence lol. Will you ask then?

[Sukkeralf]

jep

[E_L]

KEYTRUDA Sales Grew 62% to $3.1 Billion. For the quarter that is...not for the year...